OCGNHIGH SIGNALFINANCIAL10-K

OCGN shows deteriorating financial position with substantially reduced current assets, increased losses, and higher cash burn amid clinical trial progression.

The company's current assets declined significantly to $24.3M while operating losses widened, indicating accelerating cash consumption during Phase 3 trial activities. With cash reserves dropping to $39.5M and operating cash flow worsening, the company faces increasing pressure to secure additional funding or achieve clinical milestones that could attract partnership opportunities.

Comparing 2026-03-04 vs 2025-03-05View on EDGAR →
FINANCIAL ANALYSIS

OCGN's financial position weakened substantially with current assets falling 60% and total assets declining 47%, while operating losses expanded due to higher R&D spending of $39.8M supporting clinical trials. The company's cash burn accelerated with operating cash flow reaching -$57.0M, though debt levels remained modest at $1.7M. Capital expenditures dropped sharply to $185K, suggesting focus on operational rather than infrastructure investments during this critical clinical development phase.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-94.5%
$3.4M→$185K

Capex reduced 94.5% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Interest Expense
P&L
-89%
$721K→$79K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Current Assets
Balance Sheet
-60.5%
$61.7M→$24.3M

Current assets declined 60.5% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-47.2%
$82.4M→$43.5M

Total assets contracted 47.2% — asset sales, write-downs, or balance sheet optimization underway.

Operating Cash Flow
Cash Flow
-35.2%
-$42.1M→-$57.0M

Operating cash flow fell 35.2% — earnings quality concerns; investigate working capital changes and non-cash items.

Cash & Equivalents
Balance Sheet
-26.2%
$53.5M→$39.5M

Cash decreased 26.2% — monitor burn rate and upcoming capital needs.

Net Income
P&L
-25.5%
-$54.1M→-$67.8M

Net income declined 25.5% — review whether driven by operations, interest costs, or non-recurring items.

R&D Expense
P&L
+23.7%
$32.1M→$39.8M

R&D investment increased 23.7% — signals commitment to future product development, though near-term margin impact.

Total Debt
Balance Sheet
-16.8%
$2.1M→$1.7M

Debt reduced 16.8% — deleveraging strengthens balance sheet and reduces financial risk.

Operating Income
P&L
-14.9%
-$54.8M→-$62.9M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

LANGUAGE CHANGES
NEW — 2026-03-04
PRIOR — 2025-03-05
ADDED
As of February 24, 2026 , there were 327,897,296 outstanding shares of the registrant's common stock, $0.01 par value per share.
Our First-in-class, breakthrough modifier gene therapy platform presents a potential paradigm shift in treating inherited retinal diseases and blindness diseases affecting millions across the globe.
Our technology pipeline includes: Novel Modifier Gene Therapy Platform OCU400 - Based on the use of nuclear hormone receptors ("NHRs"), we believe our novel modifier gene therapy platform has the potential to address major blindness diseases, including rare genetic diseases such as RP (OCU400), with a gene-agnostic approach.
OCU400 is intended for early to advanced cases of RP including clinical and/or genetic diagnosis with both syndromic and non-syndromic forms of the disease.
In January 2025, we announced positive two-year data for multiple mutations from the Phase 1/2 clinical trial for OCU400.
+7 more — sign up free →
REMOVED
As of February 26, 2025 , there were 292,014,470 outstanding shares of the registrant's common stock, $0.01 par value per share.
OVERVIEW We are a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics and vaccines that improve health and offer hope for patients across the globe.
Our technology pipeline includes: Modifier Gene Therapy Platform Based on the use of nuclear hormone receptors ("NHRs"), we believe our modifier gene therapy platform has the potential to address many retinal diseases, including rare genetic diseases such as RP (OCU400), with a gene-agnostic approach.
We also believe our modifier gene therapy platform has the potential to address multifactorial retinal diseases including dry age-related macular degeneration ("dAMD"), which affects millions of patients in the United States alone, using OCU410, and Stargardt disease, which is a rare genetic disease, using OCU410ST.
We are actively recruiting patients in the United States and Canada in the Phase 3 liMeliGhT clinical trial for OCU400 for the treatment of RP and are on track to complete enrollment in the first half of 2025.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →